Methods and products for transfecting cells

Patent metadata

Field	Value
Publication number	US-12559772-B2
Application number	US-202318332620-A
Country	US
Kind code	B2
Filing date	Jun 9, 2023
Priority date	Dec 5, 2011
Publication date	Feb 24, 2026
Grant date	Feb 24, 2026

Abstract

The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using RNA are disclosed. Methods for producing cells from patient samples, cells produced using these methods, and therapeutics comprising cells produced using these methods are also disclosed.

First claim

What is claimed is:

1 . A method for preparing a gene-edited hematopoietic cell, the method comprising transfecting a hematopoietic cell with an in vitro transcribed synthetic RNA molecule encoding a gene-editing protein, wherein the hematopoietic cell expresses the gene-editing protein, and wherein the gene-editing protein comprises a DNA-binding domain and a nuclease catalytic domain that causes a double-strand break in the DNA of the hematopoietic cell to reduce the function of a CCR5 gene, a CXCR4 gene, or both.

2 . The method of claim 1 , wherein the gene-editing protein comprises a zinc-finger nuclease, a TALE-nuclease, a meganuclease, or an endonuclease.

3 . The method of claim 1 , wherein the in vitro transcribed synthetic RNA molecule is transcribed from a DNA template.

4 . The method of claim 3 , wherein the DNA template encodes a plurality of monomer repeats, wherein each monomer repeat comprises a repeat variable domain (RVD), and wherein the plurality of monomer repeats is selected to target a sequence within the DNA of the hematopoietic cell.

5 . The method of claim 1 , further comprising contacting the hematopoietic cell with at least one of poly-L-lysine, poly-L-ornithine, RGD peptide, fibronectin, vitronectin, collagen, and laminin.

6 . The method of claim 1 , further comprising contacting the hematopoietic cell with a medium.

7 . The method of claim 6 , wherein the medium is substantially free of immunosuppressants.

8 . The method of claim 1 , wherein the hematopoietic cell is a human cell.

9 . The method of claim 8 , wherein the hematopoietic cell is a hematopoietic stem cell or a white blood cell.

10 . The method of claim 1 , wherein the in vitro trancribed synthetic RNA molecule is complexed with a transfection reagent.

11 . The method of claim 10 , wherein the transfection reagent is lipid-based, polymer-based, or peptide-based.

12 . The method of claim 11 , wherein the transfection reagent comprises a charged polymer, a cell-penetrating peptide, a cationic lipid, a liposome, a micelle, or combinations thereof.

13 . The method of claim 1 , wherein the in vitro trancribed synthetic RNA molecule comprises at least one non-canonical nucleotide selected from the group consisting of: a 5-methyluridine residue, a pseudouridine residue, a 5-methylpseudouridine residue, a 5-hydroxyuridine residue, a 5- hydroxypseudouridine residue, and a 5-methylcytidine residue.

14 . The method of claim 1 , wherein the in vitro trancribed synthetic RNA molecule comprises uridine residues.

15 . The method of claim 14 , wherein between 20% and 100% of the uridine residues are 5-hydroxyuridine residues.

16 . The method of claim 1 , wherein the in vitro trancribed synthetic RNA molecule comprises one or more of a 5′-cap, a 5′-cap 1 structure, and a 3′-poly (A) tail.

17 . The method of claim 1 , further comprising obtaining the hematopoietic cell by reprogramming a skin cell into the hematopoietic cell.

18 . The method of claim 17 , wherein the skin cell is harvested from a patient or biopsy sample.

19 . The method of claim 17 , wherein the skin cell is selected from the group consisting of: a fibroblast, a keratinocyte, a melanocyte, an adipocyte, a mesenchymal stem cell, and an adipose stem cell.

Assignees

• Factor Bioscience Inc

Inventors

• Angel Matthew
• Rohde Christopher

Classifications

• A61K2035/124

  the cells being hematopoietic, bone marrow derived or blood cells · CPC title

• A61K35/28

  Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12N2506/09

  from epidermal cells, from skin cells, from oral mucosa cells · CPC title

• C12N2501/91

  Heparin · CPC title